- Details
- Rashid Sayyid and Zach Klaassen discuss the PI-CAI Challenge, an international study comparing artificial intelligence (AI) to radiologists in prostate cancer detection using MRI. The study develops and validates an AI system using a large dataset of prostate MRIs, comparing its performance to both study radiologists and real-world radiology readings. The AI system demonstrates superiority to stud...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines. They focus on non-hormonal systemic therapy, highlighting significant changes, particularly the emergence of PARP inhibitors like olaparib and rucaparib. The discussion covers their monotherapy and combination therapies, emphasizing the stronger endorsement for PARP inhibitors in patients with BRCA mut...
|
- Details
- Rashid Sayyid and Zach Klaassen explore the findings of the ProScreen trial, a rigorous examination into sequential prostate cancer screening using PSA, a kallikrein panel, and MRI. Highlighting the study's aim to refine screening methods by enhancing detection rates of high-grade cancers while reducing unnecessary diagnoses of low-grade conditions, they delve into the process and preliminary resu...
|
- Details
- Rashid Sayyid and Zach Klaassen dissect the EV-302 trial, presenting enfortumab vedotin and pembrolizumab as a first-line treatment for advanced urothelial cancer. This trial, marked by its publication in The New England Journal of Medicine, challenges the four-decade reign of platinum-based chemotherapy, revealing its limitations, particularly a median overall survival of merely 15-16 months. Dr....
|
- Details
- Rashid Sayyid and Zach Klaassen delve into the significance of racial disparities in prostate cancer treatment through a subgroup analysis of the ARASENS trial, which notably focused on Black patients. This pivotal trial assessed the efficacy of adding darolutamide to ADT and docetaxel in metastatic hormone-sensitive prostate cancer, revealing that Black patients, despite historically higher morta...
|
- Details
- Matthew Cooperberg introduces the inaugural patient-oriented journal club for patients diagnosed with prostate cancer. This patient journal club aims to highlight prostate cancer research, selected trials, and pivot to open discussion between expert clinicians and patients. The 15-year update from the ProtecT trial, led by Professors Freddie Hamdy and Jenny Donovan is the selected trial for this s...
|
- Details
- In this Prostate Cancer Patient Journal Club discussion, Matthew Cooperberg and Jenny Donovan address quality-of-life outcomes from the ProtecT trial's surveillance group. Jenny notes that those who did not progress avoided radical treatment impacts, with no significant quality of life difference compared to radically treated patients. Group discussion includes side effects and global variability...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trials in bladder cancer. They focus on low and intermediate-risk non-muscle invasive bladder cancer, emphasizing the need for well-designed trials to advance treatment. The panel, comprising 25 multidisciplinary experts, aims to guide late-phase...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group on clinical trial designs for bladder cancer. They focus on locally advanced and metastatic urothelial carcinoma, emphasizing the need for new treatments and rational trial designs. The panel, comprising 25 multidisciplinary experts, aims to guide late-pha...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trial design in high-risk non-muscle-invasive bladder cancer. The consensus statement, led by Dr. Ashish Kamat and published in the Journal of Clinical Oncology, aims to guide investigators in late-phase clinical trial design. The panel, comprisi...
|
